MIFH
ADPT icon

Migdal Insurance & Financial Holdings’s Adaptive Biotechnologies ADPT Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-14,169
Closed -$570K – 581
2021
Q1 		$570K Buy
14,169
+8,793
+164% +$476K 0.01% 305
2020
Q4 		$318K Buy
+5,376
New +$277K ﹤0.01% 252

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Migdal Insurance & Financial Holdings's ADPT Position: Q2 2021 in Review

Migdal Insurance & Financial Holdings sold out of Adaptive Biotechnologies (ADPT) in Q2 2021, closing a stake of 14,169 shares — an estimated $570K sold.

Migdal Insurance & Financial Holdings first reported a position in ADPT in Q4 2020 and held it in 2 quarters. The position peaked at $570K in Q1 2021. 230 funds tracked by Wall St. Rank hold ADPT as of Q2 2021.

  • Migdal Insurance & Financial Holdings reported no remaining Adaptive Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 14,169 Adaptive Biotechnologies shares in Q2 2021, an estimated $570K.
  • Migdal Insurance & Financial Holdings first reported a position in Adaptive Biotechnologies in Q4 2020 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Adaptive Biotechnologies position peaked at $570K in Q1 2021.
  • 230 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2021.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q2 2021, filed 4 Aug 2021.